01—Abstract
Summary
Summary of the 10-K filed June 19, 2020. Cited figures are marked; the original filing is the authoritative source.
Medtronic plc's 2020 Form 10-K, covering the fiscal year ending April 23, 2020, details a challenging year significantly impacted by the COVID-19 pandemic.
The company experienced a 5%a decrease in net sales compared to the prior fiscal year, largely due to disruptions in medical procedures and changes in customer buying patterns stemming from the pandemic in the fourth quarter. Despite these headwinds, Medtronic maintained a strong focus on its core strategies of therapy innovation, globalization, and economic value. Operationally, Medtronic navigated supply chain disruptions and increased costs related to pandemic safety measures.
The company's diverse product portfolio includes offerings across Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes segments. While most segments saw declines, the Respiratory, Gastrointestinal, & Renal division saw a modest increase driven by demand for ventilators and airway products during the pandemic. The company remains committed to its mission of alleviating pain, restoring health, and extending life, continuing to invest in research and development to drive future growth and address unmet patient needs.
02—Key points
Key Highlights
- Net sales decreased by 5% year-over-year to $28.9 billion, primarily due to the impact of COVID-19 on procedure volumes and customer behavior in the fourth quarter of fiscal year 2020.
- The COVID-19 pandemic significantly impacted operations, leading to supply chain disruptions, increased costs related to safety measures, and a need to reprioritize capital deployment.
- Medtronic's business is diversified across four key segments: Cardiac and Vascular (down 9%), Minimally Invasive Therapies (down 1%), Restorative Therapies (down 6%), and Diabetes (down 1%).
- The Respiratory, Gastrointestinal, & Renal division within Minimally Invasive Therapies saw a 4% increase in net sales, driven by elevated demand for ventilators and airway products due to the pandemic.
- The company continued its focus on innovation, evidenced by product launches and advancements within various segments, such as the Micra AV transcatheter pacing system and the Evolut PRO+ transcatheter aortic valve.
- Medtronic maintained a strong liquidity position with $10.9 billion in cash and investments and an undrawn $3.5 billion credit facility as of April 24, 2020.
- Share repurchases were deprioritized due to COVID-19, with no shares repurchased in March and April of fiscal year 2020, though a significant amount remained authorized for future repurchases.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2020, Medtronic plc kept $0.17.
- Revenue$28.91B100.0%
- Cost of revenue−$9.42B32.6%
- Gross profit$19.49B67.4%
- Operating costs−$14.70B50.8%
- Operating income$4.79B16.6%
- Interest, other & tax$15.0M0.1%
- Net income$4.81B16.6%
Where FY2020 revenue went
$28.91B- SG&A: $10.11B, 35% of revenue
- Cost of revenue: $9.42B, 33% of revenue
- Operating income: $4.79B, 17% of revenue
- Other operating costs: $4.59B, 16% of revenue
Kept 17% as operating income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2020filed June 19, 2020Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $28.91B$30.56B | −5.4% |
| Cost of Revenue | $9.42B$9.15B | +2.9% |
| Gross Profit | $19.49B$21.40B | −8.9% |
| SG&A Expenses | $10.11B$10.42B | −3.0% |
| Operating Income | $4.79B$6.27B | −23.6% |
| Interest Expense | $1.09B$1.44B | −24.4% |
| Net Income | $4.81B$4.65B | +3.4% |
| EPS (Basic) | $3.57$3.44 | +3.8% |
| EPS (Diluted) | $3.54$3.41 | +3.8% |
| Shares Outstanding (Basic) | 1.34B1.35B | −0.4% |
| Shares Outstanding (Diluted) | 1.35B1.36B | −0.5% |
05—Questions
Frequently Asked Questions
How did the COVID-19 pandemic affect Medtronic's financial performance in fiscal year 2020?
The COVID-19 pandemic had a significant adverse impact on Medtronic's financial performance, particularly in the fourth quarter of fiscal year 2020. Net sales decreased by 5% year-over-year due to a decline in medical procedure volumes as hospitals diverted resources to pandemic response and many elective procedures were postponed. This also led to changes in customer buying patterns and increased operational costs related to safety measures.
What are Medtronic's primary growth strategies?
Medtronic's primary growth strategies are Therapy Innovation, which involves a strong launch cadence of new therapies and procedures; Globalization, focusing on addressing healthcare inequity, particularly in emerging markets; and Economic Value, aiming to lead in value-based healthcare by improving outcomes and lowering costs through new services and solutions.
How is Medtronic managing its debt and capital?
Medtronic maintained a strong financial position with $10.9 billion in cash and investments and an undrawn $3.5 billion credit facility as of April 24, 2020. The company has no public debt maturing until March 2021. While debt service obligations are significant, the company is focused on capital allocation decisions that support its long-term strategies, including returning value to shareholders through dividends and, historically, share repurchases, although these were deprioritized due to COVID-19.
Which of Medtronic's business segments were most impacted by the pandemic?
Most of Medtronic's businesses were affected by a decline in procedure volumes due to the pandemic. Specifically, the Cardiac and Vascular Group saw a 9% decrease in net sales, and the Restorative Therapies Group experienced a 6% decline. These segments typically involve procedures that were more likely to be deferred during the pandemic.
06—Continue